Get Indexology® Blog updates via email.


Tag Archives: equities

Jan 9, 2024

Getting to Know the SPIVA After-Tax Scorecard

What do the SPIVA Scorecard results look like once you factor in taxes? Join S&P DJI’s Anu Ganti and Joseph Nelesen for a deep dive into key findings from the inaugural SPIVA After-Tax Scorecard.

READ

Dec 6, 2023

Happy Days for How Long?

With less than a month left to go to close out the year, it’s a good time to reflect on the highs and lows that market participants have experienced. While the year began with a rocky start due to the Silicon Valley Bank collapse, the market continued to power forward, stumbling in Q3 as 10-year…

READ

Sep 25, 2023

Splitting Size in U.S. Equities: S&P DJI versus MSCI in H1 2023

The first half of 2023 saw a strong rebound from 2022 for equities: the S&P 500® gained 17% as the U.S. outperformed the S&P Global Ex-U.S. BMI (up 10%). Information Technology led the way across the U.S. cap spectrum, possibly reflecting investors’ expectations regarding the potential impact of artificial intelligence. The S&P Composite 1500® combines…

READ

Apr 18, 2023

The Same, Only Different

In the first quarter of 2023, the best performing of the 17 factor indices featured in our monthly factor dashboard was S&P 500® High Beta (up 12.5%), while the worst performer was S&P 500 Momentum (-3.2%). This may seem odd at first blush, since both indices are, in some sense, performance chasers—Momentum in absolute and…

READ

Apr 18, 2023

Global Islamic Indices Gained over 10% in Q1 2023, Outperforming Conventional Benchmarks

Global equities ended the first quarter of the year with a gain of 6.9%, as measured by the S&P Global BMI. Meanwhile, Shariah-compliant benchmarks, including the S&P Global BMI Shariah and Dow Jones Islamic Market (DJIM) World Index, also increased during the quarter and outperformed their conventional counterparts by 3.5% and 3.4%, respectively. Overall, regional…

READ

Apr 17, 2023

SPIVA Europe 2022: Singing the Bear Market Blues

After 83% of euro-denominated pan-regional equity funds failed to outperform the S&P Europe 350® in the 10 years leading up to the start of 2022, last year brought an intriguing change in the market winds, including the end of near-zero interest rates and, along with it, higher hopes for stock-picking. There was higher dispersion and,…

READ

Apr 14, 2023

A Fast Start to 2023 for the S&P China 500 – Returning 5.0% in Q1

The S&P China 500 gained 5.0% in Q1 2023, continuing to claw back some of the losses exhibited in 2022. Developed markets broadly had a strong quarter, with Chinese equities underperforming global equities while outperforming emerging markets. Communication Services led sector performance for the start of 2023, up over 20%. Energy and Information Technology also…

READ

Apr 10, 2023

Unwisely Concentrated

Anyone familiar with our SPIVA Scorecards will recognize that most active managers fail most of the time. Anyone familiar with active managers will recognize that they can be quite creative in proposing both excuses and remedies for this historical record. One of their most persistent suggestions, in fact, is that active management simply isn’t active…

READ

Apr 5, 2023

Examining Passive Performance at the Core

How does indexing work for large-cap equities? S&P DJI’s Hamish Preston and State Street Global Advisor’s Michael Arone take a closer look at lessons from 20 years of SPIVA, including fee savings, outperformance, and what the latest GICS® changes mean for sectors and industries moving forward.

READ

Mar 27, 2023

A Year of Two Halves for Australian Large-Cap Equity Managers

The first half of 2022 brought steep and broad-based losses for Australian equity indices of all stripes. On a relative basis, however, active Australian Equity General funds had a decent start to 2022; as our SPIVA® Australia Mid-Year 2022 Scorecard reported, a (slim) majority of active managers in this category outperformed the S&P/ASX 200. Unfortunately…

READ


Get Indexology® Blog updates via email.

Indexology® Blog
Contributors

SEE ALL